Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation, Science, vol.226, issue.4678, pp.1097-1106, 1984. ,
DOI : 10.1126/science.6093263
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation, Science, vol.224, issue.4656, pp.1403-1409, 1984. ,
DOI : 10.1126/science.6610211
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy, Nature Reviews Molecular Cell Biology, vol.5, issue.1, pp.49-63, 2014. ,
DOI : 10.1038/sj.cdd.4402178
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies, Nature Reviews Cancer, vol.17, issue.2, pp.99-109, 2016. ,
DOI : 10.1101/gad.1103603
The BCL-2 protein family: opposing activities that mediate cell death, Nature Reviews Molecular Cell Biology, vol.94, issue.1, pp.47-59, 2008. ,
DOI : 10.1038/nrm1697
Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane, Genes & Development, vol.30, issue.8, pp.973-88, 2016. ,
DOI : 10.1101/gad.276725.115
Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis, Cell, vol.152, issue.3, pp.519-550, 2013. ,
DOI : 10.1016/j.cell.2012.12.031
URL : https://doi.org/10.1016/j.cell.2012.12.031
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors, Nature Reviews Drug Discovery, vol.2, issue.4, pp.273-84, 2017. ,
DOI : 10.1002/prot.24816
An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.360, issue.7042, pp.677-81, 2005. ,
DOI : 10.1016/0014-5793(95)00062-E
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity, The Lancet Oncology, vol.11, issue.12, pp.1149-59, 2010. ,
DOI : 10.1016/S1470-2045(10)70261-8
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, Journal of Clinical Oncology, vol.30, issue.5, pp.488-96, 2012. ,
DOI : 10.1200/JCO.2011.34.7898
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor, Cancer Research, vol.68, issue.9, pp.3421-3429, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-5836
URL : http://cancerres.aacrjournals.org/content/canres/68/9/3421.full.pdf
Programmed Anuclear Cell Death Delimits Platelet Life Span, Cell, vol.128, issue.6, pp.1173-86, 2007. ,
DOI : 10.1016/j.cell.2007.01.037
URL : https://doi.org/10.1016/j.cell.2007.01.037
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, The Lancet Oncology, vol.17, issue.6, pp.768-78, 2016. ,
DOI : 10.1016/S1470-2045(16)30019-5
Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.1, pp.230-233, 2009. ,
DOI : 10.1016/j.bmcl.2008.10.113
Evaluation and critical assessment of putative MCL-1 inhibitors, Cell Death & Differentiation, vol.15, issue.11, pp.1475-84, 2013. ,
DOI : 10.1593/neo.13230
URL : http://www.nature.com/cdd/journal/v20/n11/pdf/cdd201379a.pdf
New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them, 2013. ,
Enthalpic Efficiency of Ligand Binding, Journal of Chemical Information and Modeling, vol.50, issue.9, pp.1536-1577, 2010. ,
DOI : 10.1021/ci100125a
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia, Blood, vol.111, issue.4, pp.2300-2309, 2008. ,
DOI : 10.1182/blood-2007-06-098012
The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated, Cell Death Differ, vol.3, pp.113-121, 1996. ,
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737, Journal of Clinical Investigation, vol.117, issue.1, pp.112-133, 2007. ,
DOI : 10.1172/JCI28281DS1
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-59, 2015. ,
DOI : 10.18632/oncotarget.3275
URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=3275&path%5B%5D=7896
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile, Blood, vol.99, issue.7, pp.2285-90, 2002. ,
DOI : 10.1182/blood.V99.7.2285
Expression Is a Prognostic Marker for the Activated B-Cell???Like Type of Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.24, issue.6, pp.961-969, 2006. ,
DOI : 10.1200/JCO.2005.03.4264
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia, Blood, vol.87, pp.1140-1146, 1996. ,
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53, Blood, vol.109, issue.6, pp.2589-96, 2007. ,
DOI : 10.1182/blood-2006-02-004234
URL : http://www.bloodjournal.org/content/bloodjournal/109/6/2589.full.pdf
Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia, American Journal of Clinical Pathology, vol.55, issue.2, pp.219-248, 2000. ,
DOI : 10.1038/bjc.1997.60
URL : https://academic.oup.com/ajcp/article-pdf/113/2/219/4983459/ajcpath113-0219.pdf
MiR-15a and miR-16-1 cluster functions in human leukemia, Proceedings of the National Academy of Sciences, vol.5, issue.13, pp.5166-71, 2008. ,
DOI : 10.1093/nar/gni178
URL : http://www.pnas.org/content/105/13/5166.full.pdf
miR-15 and miR-16 induce apoptosis by targeting BCL2, Proceedings of the National Academy of Sciences, vol.101, issue.11, pp.13944-13953, 2005. ,
DOI : 10.1002/cncr.20696
URL : http://www.pnas.org/content/102/39/13944.full.pdf
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine, Cancer Discovery, vol.2, issue.3, pp.214-240, 2012. ,
DOI : 10.1158/2159-8290.CD-12-0012
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, issue.26, pp.4111-4120, 2014. ,
DOI : 10.1182/blood-2014-03-560284
URL : http://www.bloodjournal.org/content/bloodjournal/123/26/4111.full.pdf
Potential mechanisms of resistance to venetoclax and strategies to circumvent it, BMC Cancer, vol.15, issue.1, p.399, 2017. ,
DOI : 10.1016/j.clml.2015.03.006
URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3383-5?site=bmccancer.biomedcentral.com
Targeting MCL-1/ BCL-XL Forestalls the Acquisition of Resistance to ABT- 199 in, Acute Myeloid Leukemia. Sci Rep, vol.6, p.27696, 2016. ,
Structure-guided design of a selective BCL-XL inhibitor, Nature Chemical Biology, vol.60, issue.6, pp.390-397, 2013. ,
DOI : 10.1107/S0907444904019158
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy, Science Translational Medicine, vol.29, issue.279, pp.279-319, 2015. ,
DOI : 10.1007/978-1-60327-017-5_11
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.318, issue.7626, pp.477-82, 2016. ,
DOI : 10.1038/318533a0
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death & Disease, vol.15, issue.1, p.1590, 2015. ,
DOI : 10.1172/JCI39964
URL : http://www.nature.com/cddis/journal/v6/n1/pdf/cddis2014561a.pdf
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization, Analytical Biochemistry, vol.332, issue.2, pp.261-73, 2004. ,
DOI : 10.1016/j.ab.2004.05.055
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.53, issue.7391, pp.603-610, 2012. ,
DOI : 10.1002/pbc.20697
URL : http://europepmc.org/articles/pmc3320027?pdf=render